Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- VDyne, Inc.
- 入组人数
- 120
- 试验地点
- 40
- 主要终点
- The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE)
研究概览
简要总结
The purpose of this clinical study is to collect safety and efficacy data of the VDyne System to support Conformitè Europëenne (CE) Mark of the VDyne System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe or greater tricuspid valve regurgitation of primary or secondary etiology.
- •NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
- •Subject is adequately treated with medical therapy for heart failure >30 days prior to index procedure, including a diuretic.
- •Heart Team determines patient is a recommended candidate for the VDyne System.
- •Age 18 years or older at time of the index procedure.
- •Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.
排除标准
- •VDYNE SYSTEM SUITABILITY
- •Patient anatomy (cardiac and vascular) is not suitable for the VDyne System as assessed by Imaging Core Labs, Sponsor and/or Clinical Screening Committee (CSC)
- •Intolerance to procedural anticoagulation or post-procedural antiplatelet/anticoagulation regimen that cannot be medically managed
- •Hypersensitivity to nickel or titanium
- •CLINICAL EXCLUSION CRITERIA (assessed by pre-procedural imaging)
- •Left Ventricular Ejection Fraction (LVEF) <30%
- •Severe RV dysfunction as assessed by the Clinical Screening Committee (CSC).
- •Significant abnormalities of the tricuspid valve and sub-valvular apparatus
- •Sepsis including active infective endocarditis (IE) (within the last 6 months)
- •Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
- •Severe tricuspid annular or leaflets calcification
- •Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg or pulmonary vascular resistance (PVR) >5 wood units as determined by RHC.
- •History of rheumatic fever that impacts the native tricuspid valve or surrounding structures.
- •CONCOMITANT PROCEDURES
- •Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease (CAD).
- •Any planned surgery or interventional procedure within 30 days prior to or following the implant procedure. This includes any planned concomitant cardiovascular procedure [e.g. Coronary Artery Bypass Grafting (CABG), percutaneous coronary intervention (PCI), pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.]
- •Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound)
- •Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
- •Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
- •Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
- •Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.)
- •Significant valvular heart disease requiring intervention other than the tricuspid valve
- •Known significant intracardiac shunt [e.g. septal defect), patent foramen ovales (PFOs) without significant shunts are allowed]
- •COMORBIDITIES
- •Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure
- •Severe lung disease [severe chronic obstructive pulmonary disease (COPD) or continuous use of home oxygen or oral steroids]
- •Acute myocardial infarction (AMI) within 30 days
- •Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis
- •End-stage liver disease (MELD > 11 and Child-Pugh class C)
- •Bleeding requiring transfusion within 30 days
- •Coagulopathy or other clotting disorder that cannot be medically managed
- •Chronic immunosuppression or other condition that could impair healing response
- •Any of the following: leukopenia, chronic anemia [Hemoglobin (Hgb) < 9], current thrombocytopenia (platelets <70), history of bleeding diathesis, or coagulopathy
- •Unwilling to receive blood products GENERAL EXCLUSION CRITERIA
- •Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically
- •Life expectancy less than 12 months due to non-cardiac comorbidities
- •Treatment is not expected to provide benefit (futile)
- •Current IV Drug user (must be free drug abuse for > 1 year)
- •Pregnant, lactating or planning pregnancy during the course of the study
- •Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees)
- •Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study
- •Patient (or legal guardian) unable or unwilling to provide written informed consent before study-specific procedures are conducted
- •Patient unable or unwilling to comply with study required testing and follow-up visits.
研究组 & 干预措施
VDyne System Treatment Arm
干预措施: VDyne Transcatheter Tricuspid Valve Replacement System (Device)
结局指标
主要结局
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE)
时间窗: 30 days post-procedure
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
Changes in quality of life as measured by the KCCQ changes.
时间窗: From Baseline to 1 month post-procedure
Changes in quality of life as measured by the KCCQ changes. Higher score indicates worse outcome.
Changes in functional capacity (6-minute walk test)
时间窗: From Baseline to 1 month post-procedure
Changes in functional capacity (6-minute walk test)
Changes in symptom status (NYHA class)
时间窗: From Baseline to 1 month post-procedure
Changes in symptom status (NYHA class)
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE)
时间窗: 30 days post-procedure
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
Change in tricuspid valve regurgitation as measured by the Imaging Core Labs
时间窗: From Baseline to 1 month post-procedure
Change in tricuspid valve regurgitation as measured by the Imaging Core Labs
Changes in quality of life as measured by the KCCQ changes.
时间窗: From Baseline to 1 month post-procedure
Changes in quality of life as measured by the KCCQ changes. Higher score indicates worse outcome.
Changes in functional capacity (6-minute walk test)
时间窗: From Baseline to 1 month post-procedure
Changes in functional capacity (6-minute walk test)
Changes in symptom status (NYHA class)
时间窗: From Baseline to 1 month post-procedure
Changes in symptom status (NYHA class)
次要结局
- Changes in quality of life as measured by the KCCQ changes.(From Baseline to 3 months, 6 months and 1 year)
- Clinical success(From implant to 1 Year post-implant)
- The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE)(From Baseline to 1 year post-procedure)
- Change in tricuspid valve regurgitation as measured by the Imaging Core Lab(From Baseline to 3 months, 6 months and 1 year)
- Intra-Procedural success(From implant start time to procedure room exit)
- Changes in symptom status (NYHA class)(From Baseline to 3 months, 6 months and 1 year)
- Changes in functional capacity (6 minute walk test)(From Baseline to 3 months, 6 months and 1 year)
- Changes in quality of life as measured by the KCCQ changes.(From Baseline to 3 months, 6 months and 1 year)